Thomas Jaenisch
Concepts (313)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 31 | 2026 | 174 | 6.230 |
Why?
| | Dengue | 28 | 2026 | 92 | 5.760 |
Why?
| | Zika Virus | 27 | 2026 | 137 | 4.180 |
Why?
| | Pregnancy Complications, Infectious | 14 | 2026 | 438 | 2.310 |
Why?
| | Disease Outbreaks | 9 | 2024 | 422 | 1.500 |
Why?
| | Microcephaly | 9 | 2023 | 106 | 1.420 |
Why?
| | Dengue Virus | 13 | 2026 | 62 | 1.100 |
Why?
| | Epidemics | 5 | 2026 | 97 | 1.080 |
Why?
| | Maternal Exposure | 2 | 2026 | 189 | 1.000 |
Why?
| | Antibodies, Viral | 16 | 2026 | 689 | 0.990 |
Why?
| | Chikungunya Fever | 9 | 2026 | 82 | 0.960 |
Why?
| | Seroepidemiologic Studies | 16 | 2025 | 171 | 0.950 |
Why?
| | Communicable Diseases | 6 | 2024 | 166 | 0.930 |
Why?
| | Malaria | 3 | 2022 | 73 | 0.870 |
Why?
| | Public Health | 7 | 2026 | 574 | 0.860 |
Why?
| | Severe Dengue | 6 | 2026 | 9 | 0.800 |
Why?
| | Brazil | 16 | 2026 | 179 | 0.790 |
Why?
| | Congenital Abnormalities | 2 | 2021 | 108 | 0.730 |
Why?
| | Malaria, Falciparum | 3 | 2012 | 32 | 0.720 |
Why?
| | Protein Array Analysis | 2 | 2020 | 56 | 0.720 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2026 | 665 | 0.710 |
Why?
| | Masks | 1 | 2022 | 70 | 0.700 |
Why?
| | Endpoint Determination | 2 | 2018 | 84 | 0.680 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1064 | 0.640 |
Why?
| | Anemia | 3 | 2022 | 190 | 0.630 |
Why?
| | Dengue Vaccines | 2 | 2018 | 11 | 0.600 |
Why?
| | Biomedical Research | 4 | 2026 | 729 | 0.600 |
Why?
| | Latin America | 9 | 2026 | 96 | 0.580 |
Why?
| | Humans | 96 | 2026 | 146342 | 0.580 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2019 | 20 | 0.570 |
Why?
| | Politics | 3 | 2025 | 89 | 0.570 |
Why?
| | Information Dissemination | 3 | 2026 | 226 | 0.560 |
Why?
| | Plasmodium falciparum | 3 | 2019 | 37 | 0.510 |
Why?
| | Parasitemia | 2 | 2021 | 15 | 0.480 |
Why?
| | Meta-Analysis as Topic | 3 | 2025 | 173 | 0.440 |
Why?
| | Prospective Studies | 18 | 2026 | 8123 | 0.440 |
Why?
| | Child Health | 1 | 2016 | 153 | 0.430 |
Why?
| | Pregnancy | 16 | 2026 | 7230 | 0.430 |
Why?
| | Fever | 3 | 2026 | 322 | 0.410 |
Why?
| | Young Adult | 25 | 2026 | 14330 | 0.410 |
Why?
| | Capital Financing | 1 | 2013 | 7 | 0.400 |
Why?
| | Chikungunya virus | 7 | 2026 | 81 | 0.400 |
Why?
| | Female | 46 | 2026 | 79499 | 0.370 |
Why?
| | Peptides | 1 | 2019 | 992 | 0.370 |
Why?
| | Communicable Diseases, Emerging | 2 | 2025 | 39 | 0.360 |
Why?
| | Child | 26 | 2026 | 22693 | 0.360 |
Why?
| | Genetic Variation | 2 | 2017 | 996 | 0.350 |
Why?
| | Asia | 6 | 2026 | 69 | 0.330 |
Why?
| | Sexual Partners | 2 | 2024 | 195 | 0.330 |
Why?
| | Mosquito Vectors | 4 | 2019 | 32 | 0.330 |
Why?
| | Emergency Responders | 2 | 2021 | 38 | 0.320 |
Why?
| | Adolescent | 23 | 2026 | 22557 | 0.320 |
Why?
| | Bayes Theorem | 2 | 2022 | 426 | 0.310 |
Why?
| | Aedes | 4 | 2019 | 67 | 0.300 |
Why?
| | Hemoglobins | 2 | 2022 | 384 | 0.300 |
Why?
| | Cohort Studies | 10 | 2026 | 6077 | 0.300 |
Why?
| | Alphavirus | 2 | 2019 | 22 | 0.300 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2021 | 188 | 0.290 |
Why?
| | Delivery of Health Care | 1 | 2016 | 947 | 0.290 |
Why?
| | Adult | 29 | 2026 | 41087 | 0.290 |
Why?
| | Alphavirus Infections | 2 | 2019 | 45 | 0.290 |
Why?
| | Pandemics | 5 | 2025 | 1707 | 0.290 |
Why?
| | Causality | 3 | 2024 | 128 | 0.280 |
Why?
| | Male | 34 | 2026 | 73396 | 0.270 |
Why?
| | Serologic Tests | 4 | 2021 | 50 | 0.270 |
Why?
| | South America | 2 | 2025 | 56 | 0.260 |
Why?
| | Viremia | 3 | 2024 | 158 | 0.260 |
Why?
| | Immunity, Humoral | 2 | 2019 | 121 | 0.250 |
Why?
| | Incidence | 7 | 2020 | 2936 | 0.250 |
Why?
| | Virus Diseases | 2 | 2019 | 219 | 0.240 |
Why?
| | Infant, Newborn | 12 | 2022 | 6460 | 0.240 |
Why?
| | Pneumonia | 1 | 2012 | 635 | 0.230 |
Why?
| | Cluster Analysis | 2 | 2019 | 496 | 0.230 |
Why?
| | Infant | 11 | 2021 | 10114 | 0.230 |
Why?
| | Orthobunyavirus | 1 | 2025 | 8 | 0.230 |
Why?
| | Bunyaviridae Infections | 1 | 2025 | 15 | 0.230 |
Why?
| | Child, Preschool | 15 | 2026 | 11913 | 0.220 |
Why?
| | Middle Aged | 19 | 2026 | 36619 | 0.220 |
Why?
| | Prevalence | 6 | 2026 | 2861 | 0.220 |
Why?
| | Arthralgia | 1 | 2026 | 66 | 0.220 |
Why?
| | Sexually Transmitted Diseases, Viral | 2 | 2024 | 11 | 0.220 |
Why?
| | Mass Media | 1 | 2025 | 36 | 0.210 |
Why?
| | Research Design | 4 | 2025 | 1143 | 0.210 |
Why?
| | Africa South of the Sahara | 2 | 2022 | 56 | 0.210 |
Why?
| | Viral Nonstructural Proteins | 2 | 2018 | 64 | 0.210 |
Why?
| | Malaria Vaccines | 2 | 2019 | 11 | 0.210 |
Why?
| | Arbovirus Infections | 1 | 2024 | 20 | 0.210 |
Why?
| | Arboviruses | 2 | 2024 | 14 | 0.210 |
Why?
| | Severity of Illness Index | 2 | 2014 | 2921 | 0.200 |
Why?
| | Risk Factors | 11 | 2026 | 10921 | 0.200 |
Why?
| | Research Personnel | 1 | 2026 | 190 | 0.200 |
Why?
| | Semantics | 1 | 2024 | 96 | 0.200 |
Why?
| | Linear Models | 2 | 2023 | 857 | 0.190 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2021 | 104 | 0.190 |
Why?
| | O'nyong-nyong Virus | 2 | 2019 | 4 | 0.190 |
Why?
| | Cytokines | 3 | 2021 | 2081 | 0.180 |
Why?
| | Toxoplasmosis | 2 | 2019 | 44 | 0.180 |
Why?
| | Social Media | 1 | 2025 | 159 | 0.180 |
Why?
| | Neurodevelopmental Disorders | 1 | 2026 | 239 | 0.180 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 59 | 0.180 |
Why?
| | Attitude of Health Personnel | 1 | 2011 | 1219 | 0.180 |
Why?
| | Oligohydramnios | 1 | 2022 | 15 | 0.180 |
Why?
| | Mosquito Control | 2 | 2014 | 30 | 0.180 |
Why?
| | World Health Organization | 4 | 2018 | 104 | 0.180 |
Why?
| | Vietnam | 4 | 2024 | 27 | 0.180 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 133 | 0.180 |
Why?
| | RNA, Viral | 4 | 2022 | 693 | 0.180 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 348 | 0.180 |
Why?
| | Endemic Diseases | 3 | 2024 | 34 | 0.170 |
Why?
| | Algorithms | 2 | 2022 | 1849 | 0.170 |
Why?
| | Ebolavirus | 1 | 2022 | 91 | 0.170 |
Why?
| | Delphi Technique | 2 | 2025 | 350 | 0.170 |
Why?
| | Motivation | 1 | 2026 | 605 | 0.170 |
Why?
| | Epitopes | 2 | 2020 | 479 | 0.170 |
Why?
| | Tanzania | 2 | 2012 | 76 | 0.160 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 39 | 0.160 |
Why?
| | Health Policy | 2 | 2014 | 399 | 0.160 |
Why?
| | Risk | 5 | 2021 | 920 | 0.160 |
Why?
| | Epitope Mapping | 1 | 2020 | 61 | 0.160 |
Why?
| | Transients and Migrants | 1 | 2020 | 28 | 0.160 |
Why?
| | Longitudinal Studies | 5 | 2026 | 3017 | 0.150 |
Why?
| | Parvovirus B19, Human | 1 | 2019 | 3 | 0.150 |
Why?
| | Rubella virus | 1 | 2019 | 7 | 0.150 |
Why?
| | Immunoglobulin M | 4 | 2026 | 284 | 0.150 |
Why?
| | Toxoplasma | 1 | 2019 | 50 | 0.150 |
Why?
| | Case-Control Studies | 4 | 2021 | 3647 | 0.150 |
Why?
| | Emigration and Immigration | 1 | 2020 | 67 | 0.150 |
Why?
| | Hydrocephalus | 1 | 2020 | 115 | 0.150 |
Why?
| | Biomarkers | 5 | 2023 | 4340 | 0.150 |
Why?
| | Phylogeny | 3 | 2019 | 924 | 0.140 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1503 | 0.140 |
Why?
| | Antibodies, Protozoan | 1 | 2019 | 41 | 0.140 |
Why?
| | Africa | 2 | 2019 | 119 | 0.140 |
Why?
| | Hospitalization | 2 | 2020 | 2475 | 0.140 |
Why?
| | Cytomegalovirus | 1 | 2019 | 172 | 0.140 |
Why?
| | Automation | 1 | 2019 | 104 | 0.140 |
Why?
| | Peptide Library | 1 | 2019 | 91 | 0.140 |
Why?
| | Genotype | 4 | 2017 | 1879 | 0.140 |
Why?
| | Viral Load | 1 | 2021 | 526 | 0.140 |
Why?
| | Serotyping | 1 | 2018 | 31 | 0.140 |
Why?
| | Premature Birth | 1 | 2022 | 390 | 0.130 |
Why?
| | Violence | 1 | 2021 | 275 | 0.130 |
Why?
| | Animals | 14 | 2026 | 38106 | 0.130 |
Why?
| | Serum | 1 | 2018 | 58 | 0.130 |
Why?
| | Phosphoinositide Phospholipase C | 1 | 2017 | 5 | 0.130 |
Why?
| | C-Reactive Protein | 1 | 2020 | 429 | 0.130 |
Why?
| | Global Health | 3 | 2019 | 403 | 0.130 |
Why?
| | Maternal-Fetal Exchange | 1 | 2018 | 171 | 0.130 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2017 | 39 | 0.130 |
Why?
| | Peptide Mapping | 1 | 2017 | 61 | 0.120 |
Why?
| | Spatio-Temporal Analysis | 3 | 2025 | 34 | 0.120 |
Why?
| | Sequence Homology | 1 | 2016 | 43 | 0.120 |
Why?
| | Blood Donors | 1 | 2018 | 145 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 846 | 0.120 |
Why?
| | Caribbean Region | 3 | 2020 | 29 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2017 | 207 | 0.110 |
Why?
| | Viral Envelope Proteins | 1 | 2016 | 97 | 0.110 |
Why?
| | Models, Theoretical | 1 | 2018 | 561 | 0.110 |
Why?
| | Antigens | 1 | 2017 | 350 | 0.110 |
Why?
| | Clinical Protocols | 1 | 2016 | 282 | 0.110 |
Why?
| | Serogroup | 3 | 2021 | 46 | 0.110 |
Why?
| | Antigens, Viral | 2 | 2018 | 186 | 0.110 |
Why?
| | Fluid Therapy | 1 | 2016 | 154 | 0.110 |
Why?
| | Immunoglobulin G | 3 | 2026 | 901 | 0.110 |
Why?
| | Antibodies | 1 | 2017 | 400 | 0.100 |
Why?
| | Environment | 1 | 2016 | 299 | 0.100 |
Why?
| | European Union | 1 | 2013 | 13 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3416 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2017 | 385 | 0.100 |
Why?
| | Mental Health | 1 | 2020 | 779 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 771 | 0.100 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 892 | 0.090 |
Why?
| | Data Interpretation, Statistical | 2 | 2025 | 368 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2026 | 6073 | 0.090 |
Why?
| | Disease Management | 1 | 2016 | 651 | 0.090 |
Why?
| | Peru | 2 | 2021 | 61 | 0.080 |
Why?
| | Sensitivity and Specificity | 4 | 2019 | 1998 | 0.080 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2010 | 33 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5439 | 0.080 |
Why?
| | Virology | 1 | 2010 | 37 | 0.080 |
Why?
| | Indian Ocean Islands | 1 | 2010 | 1 | 0.080 |
Why?
| | Cross Reactions | 2 | 2022 | 130 | 0.080 |
Why?
| | Neutralization Tests | 2 | 2021 | 74 | 0.080 |
Why?
| | Age Factors | 2 | 2020 | 3347 | 0.080 |
Why?
| | Family Characteristics | 2 | 2021 | 203 | 0.080 |
Why?
| | Kinetics | 2 | 2024 | 1553 | 0.070 |
Why?
| | Inflammation | 1 | 2021 | 2919 | 0.070 |
Why?
| | Rural Health | 1 | 2010 | 87 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2240 | 0.070 |
Why?
| | Mass Screening | 1 | 2018 | 1307 | 0.070 |
Why?
| | Disease Progression | 3 | 2026 | 2867 | 0.070 |
Why?
| | Age Distribution | 1 | 2010 | 399 | 0.070 |
Why?
| | Sexual Behavior | 2 | 2024 | 490 | 0.070 |
Why?
| | Americas | 2 | 2019 | 27 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1543 | 0.070 |
Why?
| | Colorado | 3 | 2026 | 4595 | 0.070 |
Why?
| | Coinfection | 2 | 2019 | 143 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 588 | 0.070 |
Why?
| | Aged | 7 | 2026 | 26432 | 0.060 |
Why?
| | Antigens, Protozoan | 1 | 2007 | 32 | 0.060 |
Why?
| | Risk Assessment | 1 | 2017 | 3712 | 0.060 |
Why?
| | Prenatal Care | 2 | 2019 | 310 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5899 | 0.060 |
Why?
| | Thailand | 1 | 2026 | 20 | 0.060 |
Why?
| | Logistic Models | 1 | 2012 | 2126 | 0.060 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 179 | 0.060 |
Why?
| | Genome, Viral | 2 | 2019 | 217 | 0.060 |
Why?
| | Urbanization | 2 | 2019 | 28 | 0.060 |
Why?
| | Microsatellite Repeats | 1 | 2007 | 159 | 0.060 |
Why?
| | Colombia | 1 | 2026 | 41 | 0.060 |
Why?
| | Ceratopogonidae | 1 | 2025 | 2 | 0.060 |
Why?
| | Insect Vectors | 1 | 2025 | 39 | 0.060 |
Why?
| | West Nile Fever | 1 | 2026 | 57 | 0.060 |
Why?
| | Cats | 1 | 2025 | 226 | 0.060 |
Why?
| | Quarantine | 1 | 2025 | 31 | 0.050 |
Why?
| | Tropical Climate | 2 | 2016 | 13 | 0.050 |
Why?
| | Biosurveillance | 1 | 2024 | 1 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 612 | 0.050 |
Why?
| | Common Data Elements | 1 | 2024 | 18 | 0.050 |
Why?
| | Platelet Count | 1 | 2024 | 95 | 0.050 |
Why?
| | Dogs | 1 | 2025 | 517 | 0.050 |
Why?
| | Europe | 1 | 2025 | 421 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2025 | 137 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 467 | 0.050 |
Why?
| | Forecasting | 1 | 2025 | 388 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1763 | 0.050 |
Why?
| | Bangladesh | 1 | 2023 | 64 | 0.050 |
Why?
| | Checklist | 1 | 2024 | 105 | 0.050 |
Why?
| | Altitude | 1 | 2007 | 469 | 0.050 |
Why?
| | Population Surveillance | 1 | 2026 | 481 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2024 | 267 | 0.040 |
Why?
| | Burkina Faso | 1 | 2021 | 7 | 0.040 |
Why?
| | Middle East | 1 | 2021 | 18 | 0.040 |
Why?
| | Publication Bias | 1 | 2021 | 19 | 0.040 |
Why?
| | Colostrum | 1 | 2021 | 3 | 0.040 |
Why?
| | Venezuela | 1 | 2021 | 7 | 0.040 |
Why?
| | Pregnancy Trimesters | 1 | 2021 | 20 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 142 | 0.040 |
Why?
| | Amniotic Fluid | 1 | 2021 | 75 | 0.040 |
Why?
| | Blood | 1 | 2021 | 107 | 0.040 |
Why?
| | Immunoassay | 1 | 2021 | 108 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2021 | 334 | 0.040 |
Why?
| | Immunomodulation | 1 | 2021 | 98 | 0.040 |
Why?
| | Parturition | 1 | 2020 | 72 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.040 |
Why?
| | Disease Reservoirs | 1 | 2019 | 28 | 0.040 |
Why?
| | Genes, Viral | 1 | 2019 | 88 | 0.040 |
Why?
| | Chronic Disease | 1 | 2026 | 1827 | 0.040 |
Why?
| | Geography, Medical | 1 | 2019 | 11 | 0.040 |
Why?
| | Pathology, Molecular | 1 | 2019 | 28 | 0.040 |
Why?
| | Zoonoses | 1 | 2019 | 39 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1888 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 17438 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2022 | 503 | 0.040 |
Why?
| | Primates | 1 | 2019 | 133 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1031 | 0.030 |
Why?
| | Computer Simulation | 1 | 2022 | 1014 | 0.030 |
Why?
| | Bolivia | 1 | 2018 | 64 | 0.030 |
Why?
| | Viral Plaque Assay | 1 | 2017 | 29 | 0.030 |
Why?
| | Volunteers | 1 | 2018 | 40 | 0.030 |
Why?
| | Basic Reproduction Number | 1 | 2017 | 6 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.030 |
Why?
| | Parent-Child Relations | 1 | 2020 | 266 | 0.030 |
Why?
| | Poliovirus Vaccines | 1 | 2017 | 6 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 7109 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 2017 | 41 | 0.030 |
Why?
| | Culicidae | 1 | 2017 | 33 | 0.030 |
Why?
| | United States | 2 | 2025 | 16136 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 8391 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2017 | 74 | 0.030 |
Why?
| | Phylogeography | 1 | 2017 | 52 | 0.030 |
Why?
| | Cell Surface Display Techniques | 1 | 2017 | 13 | 0.030 |
Why?
| | Iron | 1 | 2019 | 359 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 181 | 0.030 |
Why?
| | Climate Change | 1 | 2019 | 184 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 974 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1665 | 0.030 |
Why?
| | Capsid Proteins | 1 | 2017 | 94 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2018 | 247 | 0.030 |
Why?
| | Enterovirus | 1 | 2017 | 83 | 0.030 |
Why?
| | Pacific Islands | 1 | 2015 | 5 | 0.030 |
Why?
| | Immunization | 1 | 2018 | 376 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 721 | 0.030 |
Why?
| | Inpatients | 1 | 2020 | 540 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 750 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2015 | 127 | 0.030 |
Why?
| | Hospitals | 1 | 2020 | 738 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 669 | 0.030 |
Why?
| | Shock | 1 | 2016 | 101 | 0.030 |
Why?
| | Travel | 1 | 2015 | 134 | 0.030 |
Why?
| | Blood Vessels | 1 | 2016 | 164 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2014 | 133 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2092 | 0.020 |
Why?
| | Rain | 1 | 2013 | 38 | 0.020 |
Why?
| | Quality Control | 1 | 2013 | 163 | 0.020 |
Why?
| | Cell Line | 1 | 2018 | 2814 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2018 | 779 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2014 | 206 | 0.020 |
Why?
| | Computational Biology | 1 | 2017 | 678 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4351 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1512 | 0.020 |
Why?
| | Temperature | 1 | 2013 | 635 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1537 | 0.020 |
Why?
| | Hemorrhage | 1 | 2014 | 825 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1449 | 0.020 |
Why?
| | Merozoite Surface Protein 1 | 1 | 2007 | 4 | 0.020 |
Why?
| | Zimbabwe | 1 | 2007 | 76 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1493 | 0.020 |
Why?
| | Protozoan Proteins | 1 | 2007 | 88 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2014 | 1591 | 0.010 |
Why?
| | Mutation | 1 | 2017 | 4093 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 11821 | 0.010 |
Why?
|
|
Jaenisch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|